

# Resource Summary Report

Generated by [kravitz2](#) on Jul 30, 2026

## Recombinant Anti-Integrin alpha 2 antibody [EPR5788]

RRID:AB\_2833020

Type: Antibody

---

### Proper Citation

Abcam Cat# ab133557, RRID:AB\_2833020

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2833020](http://antibodyregistry.org/AB_2833020)

**Proper Citation:** Abcam Cat# ab133557, RRID:AB\_2833020

**Target Antigen:** Integrin alpha 2

**Host Organism:** rabbit

**Clonality:** recombinant

**Comments:** Applications: Flow Cyt, WB, IHC-P

**Antibody Name:** Recombinant Anti-Integrin alpha 2 antibody [EPR5788]

**Description:** This recombinant targets Integrin alpha 2

**Target Organism:** mouse, human

**Clone ID:** EPR5788

**Antibody ID:** AB\_2833020

**Vendor:** Abcam

**Catalog Number:** ab133557

**Record Creation Time:** 20250819T211559+0000

**Record Last Update:** 20250819T222342+0000

---

### Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-Integrin alpha 2 antibody [EPR5788].

No alerts have been found for Recombinant Anti-Integrin alpha 2 antibody [EPR5788].

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 6 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [kravitz2](#) .

Zaher DM, et al. (2025) Identifying the Impact of RelA Overexpression in Triple-Negative Breast Cancer Cells Using Mass Spectroscopy-based Proteomics and Metabolomics Analysis. *Chemistry & biodiversity*, e00717.

Deng T, et al. (2025) CINTER-seq: Chemical profiling reveals interaction-dependent cell landscapes and gene signatures in vivo. *Immunity*, 58(9), 2336.

Chen Y, et al. (2022) Oncogenic collagen I homotrimers from cancer cells bind to  $\alpha 1$  integrin and impact tumor microbiome and immunity to promote pancreatic cancer. *Cancer cell*, 40(8), 818.

Hu HT, et al. (2021) Ultracentrifugal separation, characterization, and functional study of extracellular vesicles derived from serum-free cell culture. *STAR protocols*, 2(3), 100625.

Oggero S, et al. (2021) Extracellular vesicles from monocyte/platelet aggregates modulate human atherosclerotic plaque reactivity. *Journal of extracellular vesicles*, 10(6), 12084.

Nishimura T, et al. (2021) Filopodium-derived vesicles produced by MIM enhance the migration of recipient cells. *Developmental cell*, 56(6), 842.